Drug news
European Patent Office invalidates Sprycel (dasatinib) composition of matter patent.- BMS
BMS announced that the European Patent Office (EPO) upheld a decision with regard to European Patent No. 1169038 (the '038 patent), the Composition of Matter patent covering dasatinib, the active ingredient in Sprycel. The EPO upheld a decision that found the patent to be invalid. This decision does not impact BMS patents outside of the EU or other Sprycel-related patents.
Comment: Sprycel is still covered by its patents in the U.S. and EU exclusivity was due to expire in 2020.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.